For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM EMOLLIENT. Light Liquid Paraffin Emollient

Similar documents
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory DERMOCALM LOTION. Calamine and Light Liquid Paraffin Lotion

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL CREAMY WASH. Benzoyl Peroxide Creamy Wash 4%

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL HYDROPHASE. Benzoyl Peroxide Cream IP

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEDAX -5 LOTION. Permethrin Lotion 5% w/w

POLYTAR Plus Liquid PRODUCT INFORMATION. Polytar Plus Liquid medicated scalp cleanser, contains coal tar solution.

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

EMOLLIENTS. NEW 500g NEW. pump. Up to 37% Wider choice, greater savings! cost savings. without compromising on quality or patient care!

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory T-BACT OINTMENT. Mupirocin Ointment IP

Each gram of mupirocin ointment contains 20 mg of mupirocin (2% w/w) as the active ingredient.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BACTROBAN CREAM. Mupirocin Cream USP

SUMMARY OF PRODUCT CHARACTERISTICS

4.3. Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

New Zealand Datasheet

Package leaflet: Information for the user. ZORAC 0.05% gel ZORAC 0.1% gel. Tazarotene

BACTROBAN OINTMENT. Mupirocin free acid. Bacterial skin infections, e.g. impetigo, folliculitis and furunculosis.

SUMMARY OF PRODUCT CHARACTERISTICS

New Zealand Datasheet

BACTROBAN CREAM QUALITATIVE AND QUANTITATIVE COMPOSITION

DAKTARIN. Miconazole, Miconazole nitrate CREAM, POWDER, SPRAY POWDER, LOTION, TINCTURE PRODUCT INFORMATION

MUPINASE Ointment/ Cream (Mupirocin)

Prescribing Information. phisohex (hexachlorophene) Bottles of 150 ml, 450 ml. Pharmaceutical standard: USP. Antibacterial Skin Cleanser

CREAMS BATH SOAP SUBSTITUTES OINTMENT GEL ADDITIVES. NEW 500g. pump

PRODUCT INFORMATION BREVOXYL CREAM

DUAL ACTION LOGO. Quinoderm 10% / 0.5% w/w Cream Benzoyl Peroxide, hydrous / Potassium Hydroxyquinoline Sulfate

DP Fusidic Acid Cream

Rheumon Gel 1 g of gel contains 50 mg of etofenamate. For use in adults.

ISOTREX GEL Isotretinoin 0.05% w/w

The solution contains isopropyl alcohol 50% v/v, propylene glycol, and water.

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. NIX Dermal Cream. Permethrin Cream, 5% w/w. Topical Scabicidal Agent

Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the

Package leaflet: Information for the user Rogaine 50 mg/g, cutaneous foam. minoxidil

Occlusal 26%w/w cutaneous solution salicylic acid

New Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Adapalene 0.1% topical gel

ACETOCAUSTIN 0,5 ml, Cutaneous solution

PACKAGE LEAFLET: INFORMATION FOR THE USER. CURANAIL 5%, medicated nail lacquer Amorolfine

Your Manufacturer. of Pharmaceuticals. Licensing & Contract manufacturing

PATIENT INFORMATION LEAFLET. Hydromol HC Intensive Hydrocortisone and urea

New Zealand Data Sheet

PACKAGE LEAFLET. EN Elastoplast Heat Plaster 11 mg January

Consumer Medicine Information. Topical Cream Clotrimazole 10 mg/g & Hydrocortisone 10 mg/g

EPIDUO GEL PRODUCT INFORMATION

PACKAGE LEAFLET: INFORMATION FOR THE USER. TRAVATAN 40 micrograms/ml eye drops, solution Travoprost

Hydroform Cream 1% Hydrocortisone (microfine) 1% w/w and clioquinol 1% w/ w

Eumovate Ointment clobetasone butyrate

PATIENT INFORMATION LEAFLET. Alphaderm 1% & 10% w/w Cream hydrocortisone and urea

Daktacort 2% / 1% w/w cream

Scabies. Dr. Ghassan Salah

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. TRAVATAN Z Travoprost Ophthalmic Solution

Package leaflet: Information for the user. Acnatac 10 mg/g mg/g gel clindamycin and tretinoin

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

What is in this leaflet 1. What Dalacin Cream is and what it is used for

Package Leaflet: Information for the User

scalp solution 5% w/v minoxidil cutaneous solution to be applied to the scalp

Package leaflet: Information for the patient. Clindamycin ABR 150 mg capsules, hard. Clindamycin ABR 300 mg capsules, hard

Eumovate Cream clobetasone butyrate

PATIENT INFORMATION LEAFLET. Timodine Cream

ClobaDerm 500 micrograms/g Cream & Ointment (clobetasol propionate)

PATIENT INFORMATION LEAFLET PUVA TREATMENT. using. Puvasoralen 1.2% Bath Lotion (8-methoxypsoralen)

Package leaflet: Information for the user. Versatis 700 mg medicated plaster Lidocaine

Package leaflet: Information for the patient. Onytec 80 mg/g medicated nail lacquer For adults Ciclopirox

Package leaflet: Information for the user. Tactuo 0.1% / 2.5% gel Adapalene/Benzoyl Peroxide

MUPIROCIN OINTMENT 2% W/W TUBE New Zealand Data Sheet

PATIENT INFORMATION LEAFLET. AMETOP GEL 4% w/w Tetracaine

Each gram of gel contains 10 mg (1%) clindamycin (as clindamycin phosphate) and 0.25 mg (0.025%) tretinoin.

ClobaDerm 0.05% w/w Cream & Ointment (clobetasol propionate)

Dermovate Scalp Application clobetasol propionate

Atopic Dermatitis (Eczema) Allergy and Immunology Awareness Program

PENTAMYCETIN is an antibiotic that: Stops the growth of bacteria Kills bacteria

WOMEN'S Regaine EXTRA STRENGTH

EpiCeram Topical therapeutic Skin Barrier Emulsion

O N C E A DAY. In this leaflet FOR WOMEN

Betnovate Scalp Application betamethasone valerate. 1 What Betnovate is and what it is used for. 2 What you need to know before you use Betnovate

PACKAGE LEAFLET: INFORMATION FOR THE USER EMLA Cream 5% (for 5 g and pre-medication packs) lidocaine 2.5%, prilocaine 2.5%

PACKAGE LEAFLET: INFORMATION FOR THE USER. Isotrex Gel isotretinoin 0.05% w/w

PACKAGE LEAFLET: INFORMATION FOR THE USER. CURANAIL 5%, medicated nail lacquer Amorolfine

Emollient Prescribing Guideline for Primary and Secondary Care April 2017

Dermovate Ointment clobetasol propionate

PRODUCT INFORMATION DIFFERIN ADAPALENE 0.1% TOPICAL GEL

Package leaflet: Information for the patient. Epiduo 0.3% / 2.5% gel adapalene / benzoyl peroxide

PRODUCT INFORMATION DALACIN T TOPICAL LOTION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. DALACIN T clindamycin 1% (10 mg/ml) (as phosphate) lotion.

PACKAGE LEAFLET: INFORMATION FOR THE USER EMLA Cream 5% (for 30 g surgical packs) lidocaine 2.5%, prilocaine 2.5%

Hydrozole Cream Hydrocortisone (microfine) 1% w/w and clotrimazole 1% w/w

Dermovate Scalp Application clobetasol propionate

SAFETY DATA SHEETS. This SDS packet was issued with item: N/A

Package leaflet: Information for the user. Trimovate Cream clobetasone 17-butyrate, calcium oxytetracycline and nystatin

PACKAGE LEAFLET: INFORMATION FOR THE USER. Schollmed Once Weekly Fungal Nail Treatment 5% w/v Medicated Nail Lacquer

PACKAGE LEAFLET: INFORMATION FOR THE USER. Clindamycin 300 mg Capsules Clindamycin (as hydrochloride)

Retin-A 0.05% w/w cream

Complete Dermal Integration. Proven Duration.

Dalacin V Cream Clindamycin phosphate

Dermovate Ointment clobetasol propionate

Care of your skin. Introduction. What can you do to help? Step 1 - Hygiene. Patient Information

Package leaflet: Information for the patient. Duac Once Daily 10mg/g + 50mg/g Gel clindamycin + anhydrous benzoyl peroxide

Product Name: Acne Medication Benzoyl Peroxide 10% Lotion Synonyms: None. Emergency telephone number: CHEMTREC

Evaluation of Cosmeceutical Ingredients: What the Label May Not Reveal Patrick Bitter, MD. Regulation of Topical Skin Care Products.

KWELLADA-P CREME RINSE Permethrin Crème Rinse 1% w/w

Natural skin care

MENTAX -TC (butenafine HCl) Cream, 1% Rx Only DESCRIPTION CLINICAL PHARMACOLOGY. Package Insert

A novel daily moisturizing cream for effective management of mild to moderate Atopic Dermatitis in infants and children

Transcription:

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM EMOLLIENT Light Liquid Paraffin Emollient QUALITATIVE AND QUANTITATIVE COMPOSITION Light Liquid Paraffin IP Base q.s. 63.4% w/w PHARMACEUTICAL FORM Bath additive (liquid) CLINICAL PARTICULARS Therapeutic Indications OILATUM EMOLLIENT is indicated in the treatment of contact dermatitis, atopic dermatitis, senile pruritus, ichthyosis and related dry skin conditions Posology and Method of Administration For cutaneous use only. OILATUM EMOLLIENT should always be used with water, either added to bath water, applied to wet skin or used as a shower gel. OILATUM EMOLLIENT is an effective cleanser and should be used instead of soap to cleanse the skin. OILATUM EMOLLIENT may be used as frequently as necessary. Adults, adolescents and children In an eight inch (20 cm) bath of water add 1 3 capfuls (10 30 ml) (1 capful is 10 ml). Mix well. Soak for 10 20 minutes. Gently pat the skin dry with a clean towel. In cases of extensive areas of dry skin ensure complete coverage by immersion. For skin cleansing, apply a small amount of OILATUM EMOLLIENT onto wet skin. Rinse and gently pat the skin dry with a clean towel.

Infants Add ½ - 2 capfuls (5 20 ml) to a basin of water (approximately 15 litres). Apply over entire body with a sponge. Gently pat the skin dry with a clean towel. Elderly No dosage adjustment is required in the elderly. Renal impairment No dosage adjustment is necessary. Systemic exposure to OILATUM EMOLLIENT is expected to be low following cutaneous administration because percutaneous absorption of OILATUM EMOLLIENT is very low (see Pharmacokinetics Properties). Hepatic impairment No dosage adjustment is necessary. Systemic exposure to OILATUM EMOLLIENT is expected to be low following cutaneous administration because percutaneous absorption of OILATUM EMOLLIENT is very low (see Pharmacokinetics Properties). Contraindications No contraindications identified. Special Warnings and Special Precautions for Use OILATUM EMOLLIENT should be used with caution in patients with a known sensitivity or allergy to OILATUM EMOLLIENT or to any of the excipients in the preparation. Interaction with Other Medicaments and Other Forms of Interaction No drug interaction studies have been conducted with cutaneous Light Liquid Paraffin. Considering the low level of systemic absorption, drug interactions are unlikely to occur. Pregnancy and Lactation Fertility There are no data on the use of cutaneous Light Liquid Paraffin on human fertility. Pregnancy No effects during pregnancy are anticipated, since systemic exposure to OILATUM EMOLLIENT is expected to be low.

Lactation It is not known if OILATUM EMOLLIENT is excreted in human milk. Risk to the infant is likely to be low since systemic exposure is low. Patients should be advised to ensure that any residual product is fully washed off the breast prior to breast-feeding. Effects on Ability to Drive and Use Machines There have been no studies to investigate the effect of OILATUM EMOLLIENT on driving performance or the ability to operate machinery. No effects are anticipated based on the adverse reaction profile. Undesirable Effects Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 and <1/10), uncommon ( 1/1,000 and <1/100), rare ( 1/10,000 and <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). Post-marketing data Skin and Subcutaneous Tissue Disorders Rare: Application site reactions including application site irritation, rash, erythema, pruritus Immune System Disorders Rare: Application site hypersensitivity reactions including application site dermatitis Overdose Symptoms and signs The product is intended for cutaneous use only. Accidental ingestion may cause gastrointestinal irritation with nausea, vomiting and diarrhoea. Treatment In case of accidental ingestion, management should be as clinically indicated or as recommended by the national poisons centre, where available. PHARMACOLOGICAL PROPERTIES Pharmacodynamic Properties

Pharmacotherapeutic Group Dermatologicals, other emollients and protectives (ATC code : D02AX ) Mechanism of action Light liquid paraffin is an emollient widely used in the treatment of eczema and related dry skin conditions. Pharmacodynamic effects Light liquid paraffin exerts an emollient effect by forming an occlusive film on the stratum corneum. Pharmacokinetic Properties There have been no studies to investigate the pharmacokinetics of cutaneously applied OILATUM EMOLLIENT. It is chemically and biologically inert; systemic uptake is considered to be minimal (<1%). Preclinical Safety Data Non-clinical studies have not been conducted with OILATUM EMOLLIENT. PHARMACEUTICAL PARTICULARS List of Excipients Acetylated Lanolin Alcohol, Isopropyl Palmitate, Polyethylene Glycol 400 dilaurate, Polyoxyethylene 40 sorbital septaoleate (Arlatone T), Floral Spice Incompatibilities No incompatibilities have been identified. Shelf Life 36 months. The expiry date is indicated on the label and packaging. Special Precautions for Storage Store in a cool place. Keep out of reach of children.

Nature and Specification of Container 100 ml HDPE bottle Instructions for Use / Handling For external use only. Refer section Posology and Method of Administration for information. No other special requirements. For further information please contact: Stiefel India Private Limited, Registered office : 401 & 402, A Wing, 4th Floor, Floral Deck Plaza, Opp. Rolta Bhavan, Central MIDC Road, Andheri ( E ), Mumbai- 400093 OILATUM is a trademark of the GlaxoSmithKline group of companies Version OLE/PI/IN/2013/01 dated 02 September 2013 Adapted from GDS Version 01 dated 24 September 2012